XML 75 R30.htm IDEA: XBRL DOCUMENT v3.19.3
Collaboration Agreements - Summary of Revenue Recognized under Agreement (Detail) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Total revenue $ 33,174 $ 29,027 $ 248,603 $ 104,903
License Revenue [Member]        
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Total revenue 11,935 0 162,517 14,323
Development Revenue [Member]        
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Total revenue 20,660 29,027 85,507 90,580
Astellas Agreement [Member] | License Revenue [Member] | Japan [Member]        
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Total revenue 11,935 0 11,935 14,323
Astellas Agreement [Member] | License Revenue [Member] | Europe [Member]        
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Total revenue 0 0 117,470 0
Astellas Agreement [Member] | Development Revenue [Member] | Japan [Member]        
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Total revenue 537 474 1,151 2,065
Astellas Agreement [Member] | Development Revenue [Member] | Europe [Member]        
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Total revenue 2,996 4,658 24,463 14,384
AstraZeneca Agreements [Member] | China [Member]        
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Total revenue 19 0 19 0
AstraZeneca Agreements [Member] | License Revenue [Member] | U.S./RoW and China [Member]        
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Total revenue 0 0 33,112 0
AstraZeneca Agreements [Member] | Development Revenue [Member] | U.S./RoW and China [Member]        
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Total revenue $ 17,106 $ 23,895 $ 59,872 $ 74,096